NCT05093296View on ClinicalTrials.gov

Oxytocin and Naltrexone: Investigation of Combined Effects on Stress- and Alcohol Cue-induced Craving in Alcohol Use Disorder

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

December 2, 2021

Primary Completion Date

July 15, 2023

Study Completion Date

September 27, 2023

Conditions
Alcohol Use DisorderAlcoholismAlcohol Addiction
Interventions
DRUG

Oxytocin nasal spray

24 I.U. Oxytocin nasal Spray will be administered twice on two separate trial days.

DRUG

Naltrexone Pill

All participants will receive 50mg Naltrexone daily as oral tablet throughout the study

DRUG

Placebo

Placebo nasal spray (same composition as the verum oxytocin spray except for the active ingredient oxytocin)

Trial Locations (1)

68159

Central Institute of Mental Health, Mannheim

All Listed Sponsors
collaborator

Heidelberg University - Institute of Medical Biometry (IMBI)

UNKNOWN

collaborator

Heidelberg University - Coordination Centre for Clinical Trials (KKS) of Heidelberg University

UNKNOWN

collaborator

German Federal Ministry of Education and Research

OTHER_GOV

lead

Central Institute of Mental Health, Mannheim

OTHER

NCT05093296 - Oxytocin and Naltrexone: Investigation of Combined Effects on Stress- and Alcohol Cue-induced Craving in Alcohol Use Disorder | Biotech Hunter | Biotech Hunter